Boston Tech
Apnimed Got Its Sleep Apnea Pill Into FDA Review, and Cambridge Sees a CPAP Exit Ramp
Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.
Boston Tech
Apnimed's July 14 FDA filing acceptance puts its Cambridge sleep apnea pill AD109 on track for a February 28, 2027 review decision.
Boston Tech
Spero Therapeutics won FDA approval for the first oral carbapenem in the U.S., giving Cambridge biotech a real answer to hospital-only UTI care.